Popular Articles

'Pro-choice Community' Should Find New 'Way Of Talking About Reproductive Freedom,' Opinion Piece Says
"Most of the push-back" from antiabortion-rights advocates to a recent e-mail message from author Judy Blume on behalf of Planned Parenthood -- which asked mailing list subscribers for donations -- was generated by an article in the antiabortion-rights publication LifeNews, columnist Meghan Daum writes in a Los Angeles Times opinion piece. The article put a "heavy, misrepresentative spin" on Blume"s message, which urged donors to "do all [they] can to support" the increasing number of women turning to Planned Parenthood centers for health care during the economic downturn.The LifeNews article said, "Blume notes how more women are seeking abortions from Planned Parenthood because of the difficult economy, and she urges readers of the e-mail to use that as a reason to support the abortion business." According to Daum, "this is just the kind of thing that makes abortion-rights advocates apoplectic," noting that abortion-rights advocates "fired-back" in the "blogosphere ... imparting the statistic about abortion making up only 3% of Planned Parenthood"s services and pointing out that many of the women being yelled at by picketers in clinic parking lots aren"t even pregnant but, rather, trying to avoid getting pregnant." Daum continues that the organization, much like Blume, "occupies a clear position on the post-Roe cultural map," adding, "Generally speaking, if you"re on board with abortion rights, you"re on board with Planned Parenthood." In addition, if you are against abortion rights, the "organization is the headquarters of Godlessness," she adds. Daum writes that it is not difficult to see why Planned Parenthood enlisted Blume -- an "icon of 1970s-era feminism and its efforts on behalf of sex education and women"s health" -- because she conjures "nostalgia for the early days of the fight that makes pro-choicers want to keep fighting today."Daum writes that as she watched this "saga unfold in [her] inbox," she was "struck by a troubling question. Even though Blume may not be associated with abortion in and of itself … is there something about her persona that signals a lack of dispassion about its ramifications? Is she reminding people of a time when, in the relief of Roe being decided, there was a cultural perception that abortion was a simple procedure that needn"t come with attendant emotional baggage?"Daum adds that there is "no denying that the language and overall tone around abortion has changed. Despite what many pro-life groups seem to think, most abortion-rights advocates prefer "safe, legal and rare" to "no big deal."" According to Daum, President Obama, "pro-choice though he is, is hardly strident -- and even a little evasive -- on the issue." She adds that Obama favors language about reducing the need for abortions and "finding common ground with the other side." Daum notes that the pop cultural arena "has become downright allergic to the issue" of abortion, with a recent movie coining the term "shmashmortion" because the characters "can"t even get the word out." Daum adds that although Blume "was undoubtedly effective" at bringing in funding for Planned Parenthood, perhaps what might have been "even more radical is if the pro-choice community could find a way of talking about reproductive freedom that neither reverts to the perceived casualness of the 1970s nor panders to the "shmashmortion" dialect of today. "Safe, legal and rare" comes close. But "safe, legal, rare and a big deal" might be even better" (Daum, Los Angeles Times, 5/14).
drugs without prescription
ADVTX Announces New Treatment For Bleeding After Nuclear Exposure
Advanced Therapeutics & Co. (ADVTX) announced that Fibrinoplate-S™ has shown efficacy in reducing the bleeding in animals exposed to extreme doses of radiation. Survivors of a nuclear event or a dirty bomb explosion will have similar damage from the ionizing radiation of such bombs.
News of the day
Access Pharmaceuticals Provides Update On ProLindac(TM) Phase 2 Ovarian Cancer Trial And Clinical Development Plan
ACCESS PHARMACEUTICALS, INC.(OTC Bulletin Board: ACCP), provided an update on the progress in the Company"s clinical development plan for ProLindac, a novel DACH platinum drug that has shown to be active in many solid tumor types in human clinical studies. Access recently announced positive safety and efficacy results from its Phase 2 monotherapy clinical study of ProLindac(TM) in late-stage, heavily pretreated ovarian cancer patients. In this study, 66% of patients who received the highest dose achieved clinically meaningful disease stabilization according to RECIST criteria. No patient in any dose group exhibited any signs of acute neurotoxicity, which is a major adverse side-effect of the approved DACH platinum, Eloxatin, and ProLindac was well tolerated overall. The Company has scaled up manufacturing in order to begin the next phase of clinical development. Access plans to conduct several combination trials in different solid tumor types both as Company-sponsored trials and in conjunction with its two previously announced co-development partners.
Public Health

Findings In Epilepsy Gene In Animals May Guide Treatment Directions For Infants

Researchers studying a difficult-to-treat form of childhood epilepsy called infantile spasms have developed a line of mice that experiences seizures with features closely resembling those occurring in patients with infantile seizures. These genetically engineered mice provide a new opportunity for scientists to test treatments that may benefit children. "Approximately one out of every 100 infants has a seizure. Many of them go on to have epilepsy -- characterized by recurrent seizures. One obstacle to developing better therapies for children has been the lack of a good animal model," said study leader Jeffrey A. Golden, M.D., pathologist-in-chief at The Children"s Hospital of Philadelphia. Golden"s team described a new mouse model for infantile spasms on May 12 in an online study in the journal Brain. Infantile spasms are a type of seizure that occurs in an estimated 1 in 2000 to 1 in 6000 babies, with onset between ages three months and one year. During the seizures, infants have jerking movements and abnormal brain waves (seen on EEGs). "Children with infantile spasms often have a poor developmental outcome," said Golden. "Despite current treatment, many children with infantile spasms go on to develop lifelong epilepsy and varying degrees of mental retardation." Finding a treatment for infantile spasms is crucial. "If we could better treat the infantile spasms, it is very possible some of these later problems could be prevented," added Golden. Neurologists previously knew that mutations in Arx, the X-linked aristaless-related homeobox gene, were associated with abnormal brain development, neurocognitive problems, and with childhood neurological conditions involving seizures and spasms. Golden"s team developed genetically engineered mice in which the Arx gene was removed from interneurons, a type of brain cell that inhibits electrical firing in brain circuits. Removing the gene"s role appears to have resulted in overexcited brain cells and seizures in the mice. The seizures resembled human infantile spasms. Equally exciting to the researchers, these mice had another brain wave abnormality similar to that found in children with infantile spasms -- an abnormal background EEG. "This is the first genetic model of a developmental epilepsy, and even more importantly, it was generated by mutating the same gene that can be found mutated in humans with infantile spasms," said Golden. In an unexpected development, the researchers found that half of the female mice carrying the mutation also developed seizures. Because the mutation occurs on the X chromosome, it was expected that male mice would have seizures, which was true, and that all the females would be unaffected carriers, which was not the case. This discovery prompted the researchers to take a closer look at human families with an infantile spasms patient. They found that the patients" mothers (14 women) had experienced normal development. But of the patients" nine other relatives -- sisters, aunts and a cousin -- six had neurological problems, including four with epilepsy. The neurological problems included varying degrees of mental retardation or other learning disabilities. These findings, said Golden, will immediately change the evaluation and testing of women with mental retardation and epilepsy, particularly in families with other affected individuals. This new finding will also assist genetic counselors in advising parents who already have a child with an Arx mutation and are contemplating having another child. Going forward, Golden said, this new animal model provides an important tool: an opportunity to begin testing drugs in the mice to identify potential treatments for children. "We can screen existing drugs to see if they are effective against this type of epilepsy," said Golden, adding that understanding the biological mechanism by which infantile spasms develop may also lead to more specific treatments. Golden and first author Eric D. Marsh, M.D., Ph.D., are both from Children"s Hospital and the University of Pennsylvania. Other co-authors were Amy Brooks-Kayal, of the Children"s Hospital, Denver and the University of Colorado; and faculty members of the University of Chicago; Vanderbilt University; the University of Rotterdam, Netherlands; and the University of Pennsylvania School of Medicine. The National Institutes of Health, the American Epilepsy Society/Milken Family Foundation and The Children"s Hospital of Philadelphia provided funding support for this study. Marsh et al, "Targeted loss of Arx results in a developmental epilepsy mouse model and recapitulates the human phenotype in heterozygous females," Brain, published online May 12, 2009. About The Children"s Hospital of Philadelphia: The Children"s Hospital of Philadelphia was founded in 1855 as the nation"s first pediatric hospital. Through its long-standing commitment to providing exceptional patient care, training new generations of pediatric healthcare professionals and pioneering major research initiatives, Children"s Hospital has fostered many discoveries that have benefited children worldwide. Its pediatric research program is among the largest in the country, ranking second in National Institutes of Health funding. In addition, its unique family-centered care and public service programs have brought the 430-bed hospital recognition as a leading advocate for children and adolescents. The Children"s Hospital of Philadelphia


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):